Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study - 19/04/18
Doi : 10.1016/j.jaad.2017.11.036
Jorge R. Georgakopoulos, BSc a, Arvin Ighani, BMSc b, Michelle Phung, BMSc c, Jensen Yeung, MD, FRCPC b, d, e, f, ⁎ 
a Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada
b Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
c Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada
d Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
e Women's College Hospital, Toronto, Ontario, Canada
f Probity Medical Research Inc., Waterloo, Ontario, Canada
∗Correspondence to: Jensen Yeung, MD, FRCPC, Department of Dermatology, Women's College Hospital, 76 Grenville St, Fifth Floor, Toronto M5S 1B2, Ontario, CanadaDepartment of DermatologyWomen's College Hospital76 Grenville St, Fifth FloorTorontoOntarioM5S 1B2Canada
| Funding sources: None. |
|
| Disclosure: Dr Yeung has been a speaker, consultant, and investigator for AbbVie, Allergan, Amgen, Astellas, Boehringer Ingelheim, Celgene, Centocor, Coherus, Dermira, Eli Lilly, Forward, Galderma, Janssen, Leo, Medimmune, Merck, Novartis, Pfizer, Regeneron, and Takeda. Mr Georgakopoulos, Mr Ighani, and Ms Phung have no conflicts of interest to disclose. |
|
| Reprints not available from the authors. |
© 2017
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 78 - N° 5
P. 1019-1020 - mai 2018 Retour au numéro
Article précédent
- Dermoscopy as an evolving tool to assess vitiligo activity
- Abhijeet Kumar Jha, Sidharth Sonthalia, Aimilios Lallas
- Effectiveness of low-level laser therapy in lichen planopilaris
- Pablo Fonda-Pascual, Oscar M. Moreno-Arrones, David Saceda-Corralo, Ana R. Rodrigues-Barata, Cristina Pindado-Ortega, Pablo Boixeda, Sergio Vaño-Galvan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?